Please login to the form below

Not currently logged in
Email:
Password:

rivaroxaban

This page shows the latest rivaroxaban news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Latest news

More from news
Approximately 9 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Rivaroxaban. Rivaroxaban (Xarelto; Bayer and Johnson &Johnson) is an oral, once-daily, selective factor Xa inhibitor that is approved in the EU and US for the prevention of stroke and systemic ... In addition, rivaroxaban significantly reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...